Last reviewed · How we verify
Fixed Dose Plerixafor
Plerixafor is a CXCR4 antagonist that mobilizes hematopoietic stem cells from the bone marrow into peripheral blood for collection and transplantation.
Plerixafor is a CXCR4 antagonist that mobilizes hematopoietic stem cells from the bone marrow into peripheral blood for collection and transplantation. Used for Mobilization of hematopoietic stem cells to peripheral blood for collection and autologous transplantation in patients with non-Hodgkin lymphoma and multiple myeloma.
At a glance
| Generic name | Fixed Dose Plerixafor |
|---|---|
| Also known as | Mozobil, AMD3100 |
| Sponsor | Genzyme, a Sanofi Company |
| Drug class | CXCR4 antagonist |
| Target | CXCR4 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Plerixafor blocks the CXCR4 chemokine receptor on hematopoietic stem cells, disrupting their interaction with stromal cell-derived factor-1 (SDF-1) in the bone marrow microenvironment. This causes stem cells to be released into the peripheral circulation where they can be harvested for autologous stem cell transplantation. The fixed-dose formulation provides a standardized dosing approach for this mobilization strategy.
Approved indications
- Mobilization of hematopoietic stem cells to peripheral blood for collection and autologous transplantation in patients with non-Hodgkin lymphoma and multiple myeloma
Common side effects
- Diarrhea
- Nausea
- Fatigue
- Headache
- Injection site reactions
Key clinical trials
- CHRONO-MOBILIZE: Chronotherapy of G-CSF for CD34+ Mobilization in Healthy Donors (NA)
- Plerixafor and Clofarabine in Frontline Treatment of Elderly Patients With Acute Myelogenous Leukemia (AML) (PHASE1, PHASE2)
- Granulocyte-colony Stimulating Factor (G-CSF) and Plerixafor Plus Sorafenib for Acute Myelogenous Leukemia (AML) With FLT3 Mutations (PHASE1)
- Study of AMD3100 (Plerixafor) and Rituximab in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (PHASE1)
- A Trial to Establish the Feasibility of Combining Either the Tyrosine Kinase Inhibitor AC220,CXCR4 Inhibitor Plerixafor or HSP90 Inhibitor Ganetespib With Chemotherapy in Older Patients With Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome. (PHASE1, PHASE2)
- Evaluation of Approved Weight-Based Dose Compared to Fixed Dose of Plerixafor in Patients With Non-Hodgkin's Lymphoma (NHL) Weighing Less Than 70 Kilograms (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |